Journal of Community Pharmacy Practice
Vol: 03, No. 01, Jan-June 2023
ISSN: 2799-1199, DOI: 10.55529/jcpp.33.24.32

Research Paper

Safeguarding health: The impact of pharmacovigilance practices in community pharmacies

Fahad Nabi[1], Abrar Bashir Malik[2], Mohd Altaf Dar[3*]
[1,2,3*]Department of Pharmacology, CT Institute of Pharmaceutical Sciences, PTU, Jalandhar Punjab, India.

Article Info

Article History:
Received: 15 November 2022
Revised: 23 January 2023
Accepted: 01 February 2023
Published: 16 March 2023

Keywords:
Pharmacovigilance
Community Pharmacies
Adverse Drug Reactions
Patient Safety
Risk Mitigation
Medication Safety

ABSTRACT

Background: Pharmacovigilance is the field that tracks and reviews bad reactions to medicines and other drug-related harms. It also supports steps meant to prevent these problems. The work matters for keeping patients safe and for helping medicines work as intended. In community pharmacies, it is often how risks are noticed early and acted on.
Objective: This review looks at what pharmacovigilance means in community pharmacy. The focus is on ways to help patients stay safe. It also covers how teams can support better use of medicines and steadier treatment results.
Method: For this narrative review, we looked at papers on current practice. We also reviewed issues that slow down progress in community settings. The sources included work on how ADRs are reported, how patients are taught about their medicines, and how pharmacists and other clinicians work together. The aim was to summarize methods, limits, and possible options.
Result: The review points to several key actions. One is regular and careful reporting of ADRs. Another is clear patient teaching before and after medicine starts. A third is close work with doctors and other health staff. Even with these steps, change is not easy. Some ADRs are not reported. Some sites lack staff time and other support. Training for pharmacists is still needed. Possible fixes include better ways to record and send reports, training that targets key gaps, and more consistent talk across different professions.
Conclusion: In the end, community pharmacies help protect patients when pharmacovigilance is built in. A full set of processes can reduce harm and support safer care. It can also improve the overall quality of healthcare delivery.

Corresponding Author:
Mohd Altaf Dar
Department of Pharmacology, CT Institute of Pharmaceutical Sciences, PTU, Jalandhar Punjab, India.
Email: daraltaf490@gmail.com

Journal of Community Pharmacy Practice (JCPP)

Copyright © 2023 The Author(s). This is an open access article distributed under the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. INTRODUCTION

The detection, evaluation, comprehension, and prevention of adverse drug responses (ADRs) and adverse drug events (ADEs) are the primary focuses of pharmacovigilance, which is an essential component of contemporary healthcare. Its purpose is to enhance the safety of patients and guarantee that pharmaceuticals are used in an efficient manner. Pharmacovigilance is an essential component in the management of hazards associated with medication, and it is particularly important in community pharmacies, which are the primary point of contact for patients. Because of their accessibility and knowledge, pharmacists are in a position that is unmatched in terms of their ability to recognise and resolve potential drug-related concerns that may have arisen throughout the course of medication therapy [1], [2], [3]. Community pharmacies are frequently the first places where patients interact with their drugs and in which they seek advice on how to use them. When it comes to ensuring that pharmaceuticals are taken in a manner that is both safe and effective, it is the responsibility of pharmacists to monitor for adverse drug reactions (ADRs) and to manage them. There are a number of essential actions that are required for effective pharmacovigilance procedures in community pharmacy. These activities include patient education, systematic adverse drug reaction reporting, and collaboration with other healthcare providers [3], [4], [5]. The implementation of these practices contributes to the identification and resolution of potential medication-related issues, which ultimately leads to improved patient safety and therapeutic outcomes. Pharmacists are responsible for more than just administering pharmaceuticals in the context of pharmacovigilance. Among the tasks that they perform is the monitoring of patients' responses to treatments, the identification of potential drug interactions, and the provision of essential information regarding adverse effects and the appropriate utilisation of medications. For the purpose of ensuring that patients receive the necessary care and preventing problems that are related to medication, this proactive approach is helpful.

Despite the fact that it is extremely important, pharmacovigilance in community pharmacies is confronted with a number of obstacles [5], [6], [7]. Underreporting of adverse drug reactions (ADRs), limited resources, and the requirement for continual education and training are some of these factors. In order to improve the efficiency of pharmacovigilance processes and guarantee that patients receive the greatest possible level of care, it is essential to address these problems [8].

2. RELATED WORK

There is a growing body of research that emphasises the significance of pharmacovigilance in community pharmacy, as well as its influence on the management of medications and the safety of patients. It has been established via research that the participation of pharmacists in pharmacovigilance can considerably improve the detection and management of adverse drug reactions (ADRs), which ultimately results in better patient outcomes [8], [9], [10]. A significant study was conducted to investigate the role that community pharmacists play in the detection of adverse drug reactions (ADRs). The study discovered that interventions led by pharmacists, such as patient follow-ups and medication reviews, were extremely effective in identifying and managing ADRs. Following the findings of the study, it was discovered that pharmacists who actively participated in pharmacovigilance procedures were able to identify adverse drug reactions (ADRs) that could have otherwise gone unnoticed. This resulted in timely interventions and improved patient safety results. In a different review, the favourable influence that pharmacovigilance has on lowering the number of adverse medication events that occur in community pharmacy settings was noted [10], [11], [12], [13]. The analysis highlighted the fact that

pharmacists could dramatically reduce the number of serious adverse drug reactions (ADEs) by systematically reporting and monitoring adverse drug reactions (ADRs). In addition, it was mentioned that activities conducted by pharmacists, such as medication counselling and patient education, were extremely important in determining the potential for drug-related issues and ensuring that they were appropriately managed. Despite these advantages, there are a number of obstacles that have been identified as preventing community pharmacists from practicing effective pharmacovigilance. A significant problem is the underreporting of adverse drug reactions (ADRs), which occurs when numerous adverse events are not reported because of a lack of awareness or the perception that the reporting process is too complicated. Through the implementation of user-friendly reporting methods and the enhancement of pharmacists' knowledge and training in pharmacovigilance, it has been demonstrated through studies that these problems can be addressed and the reporting rate of adverse drug reactions (ADRs) can be increased [13], [14], [15]. In addition, research has indicated that there is a requirement for a more effective incorporation of pharmacovigilance techniques into the normal operations of pharmacies. Community pharmacies that employ structured reporting and monitoring systems have been shown to have increased detection of adverse drug reactions (ADRs) and better patient outcomes, according to studies. The significance of these findings lies in the fact that ongoing efforts are required to include pharmacovigilance into the routine tasks of pharmacy practice [15], [16], [17].

3. METHODOLOGY

To conduct this review, a comprehensive search of academic and clinical databases, including PubMed, Scopus, and Google Scholar, was performed. The selection criteria focused on publications that had been peer-reviewed and published within the past ten years. These studies addressed pharmacovigilance methods in community pharmacy, their impact on patient safety, and the challenges that pharmacists encounter. The review aimed to provide a thorough assessment of the current state of knowledge by summarizing pertinent findings, recognizing emerging trends, and evaluating the influence of pharmacovigilance methods on the quality of healthcare. The purpose was to identify research gaps and discuss implications for future studies and clinical practice. Incorporating recent studies ensures that the review reflects the most up-to-date practices and challenges in the field of pharmacovigilance. Pharmacovigilance is critical in community pharmacies, where pharmacists are often the first point of contact for patients regarding medication issues. The review highlighted the significant role pharmacists play in monitoring and reporting adverse drug reactions (ADRs), ensuring medication safety, and improving patient outcomes. Pharmacists can identify potential drug interactions, educate patients on the safe use of medications, and report ADRs to relevant authorities, contributing to the overall safety of the healthcare system. One of the key findings of the review was the positive impact of pharmacovigilance methods on patient safety. By implementing systematic pharmacovigilance practices, pharmacists can detect and prevent medication errors, reducing the incidence of ADRs. This proactive approach not only enhances patient safety but also improves the quality of healthcare by ensuring that medications are used safely and effectively. The review also identified several emerging trends in pharmacovigilance within community pharmacies. One trend is the increasing use of technology to support pharmacovigilance activities. Electronic health records (EHRs), clinical decision support systems, and pharmacovigilance software tools are becoming more prevalent, helping pharmacists to track and analyze medication-related data more efficiently. These technologies enable better identification of ADRs and facilitate more accurate reporting. However, the review also noted several challenges that pharmacists face in implementing effective pharmacovigilance methods. These challenges include limited access to comprehensive patient information, time constraints, and the need for additional training and support. Overcoming these obstacles is essential to maximize the effectiveness of pharmacovigilance practices in community pharmacies. To enhance the role of pharmacists in pharmacovigilance, the review proposed several strategies. One strategy is to improve access to patient health information, allowing pharmacists to make more informed decisions about medication safety. Another strategy is to advocate for policy

changes that support pharmacists' involvement in pharmacovigilance, including providing reimbursement for pharmacovigilance activities and recognizing their contributions to patient safety. Additionally, ongoing education and training for pharmacists are crucial to keep them updated on the latest pharmacovigilance practices and technologies. The review also emphasized the importance of collaboration among healthcare providers in pharmacovigilance efforts. By working together, pharmacists, physicians, and other healthcare professionals can ensure better communication and coordination, leading to more effective detection and management of ADRs. Collaborative efforts can also facilitate the sharing of information and best practices, further enhancing the quality of pharmacovigilance in community pharmacies. The review underscores the significant impact of pharmacovigilance methods on patient safety and the quality of healthcare in community pharmacies. By implementing effective pharmacovigilance practices, pharmacists can play a crucial role in detecting and preventing ADRs, improving medication safety, and enhancing patient outcomes. Addressing the challenges they face and adopting strategies to support their role in pharmacovigilance are essential for maximizing their contributions. The findings of this review highlight the importance of continuous research and innovation in pharmacovigilance, ensuring that community pharmacies remain at the forefront of safe and effective medication management.

4. RESULTS AND DISCUSSION

The findings from the literature study shed light on the significant role that pharmacovigilance practices play in community pharmacies, as well as the impact that these practices have on the patients' safety and the management of their medications. The early detection of adverse drug reactions, the decrease of adverse drug events, and the general improvement of healthcare quality are all outcomes that can be increased by the implementation of effective pharmacovigilance. The implementation of pharmacovigilance procedures in community pharmacies has a significant role in improving the identification of adverse medication reactions [17], [18], [19], [20]. During the course of their interactions with patients, pharmacists are frequently the first to recognise indicators of adverse drug reactions (ADRs), which may include unanticipated side effects or unfavourable interactions with other medications. It has been proven through research that pharmacists who participate in pharmacovigilance procedures, such as routine medication reviews and patient follow-ups, are more likely to discover adverse drug reactions (ADRs) in comparison to those who do not participate in these practices. For instance, a study that investigated the detection of adverse drug reactions (ADRs) in community pharmacies discovered that pharmacists who carried out routine follow-ups and prescription reviews were able to identify ADRs that could have been overlooked otherwise. This resulted in prompt interventions and an improvement in patient safety. A decrease in the number of adverse drug events is another important goal of pharmacovigilance procedures, which are also essential in lowering the number of adverse drug events [20], [21], [22], [23]. Pharmacists are able to efficiently detect and manage any medication-related problems because to the systematic reporting and monitoring of adverse drug reactions (ADRs). Research has demonstrated that treatments led by pharmacists, such as patient education and medication counselling, have the potential to avoid adverse drug reactions (ADEs) or reduce their severity. Community pharmacies that had organised reporting and monitoring systems had a considerable reduction in the number of serious adverse drug reactions, according to the findings of a review that investigated the effects of pharmacist-led pharmacovigilance on adverse drug reactions (ADEs). The proactive approach that pharmacists take in recognising and correcting possible concerns before they develop into major ones is credited with contributing to this reduction [23], [24], [25], [26]. Pharmacovigilance techniques provide a substantial contribution to the education and empowerment of patients. Pharmacists are able to assist patients in making well-informed decisions on their treatments by offering information that is both clear and factual regarding pharmaceuticals. This information may include probable adverse effects as well as instructions on how to manage them. It has been demonstrated through research that patients who receive comprehensive counselling from pharmacists are more likely to be aware of potential adverse drug reactions (ADRs) and how to report and report

them. Patients are given the ability to actively participate in their own care and to solicit early assistance in the event that they feel any undesirable effects as a result of this greater awareness [26], [27], [28], [29], [30]. As an illustration, a study that was conducted on patient education in community pharmacies discovered that patients who were provided with comprehensive counselling regarding their medications were better equipped to recognise and report adverse drug reactions (ADRs), which ultimately led to improvements in medication management and safety. Despite the fact that pharmacovigilance has many advantages, there are a number of obstacles that prevent it from being very effective in community pharmacies. One of the most serious problems that continues to exist is the underreporting of adverse drug reactions (ADRs). Many adverse events are not reported because of a lack of awareness, the perceived difficulty of the reporting process, or time restrictions. It has been found through research that enhancing the knowledge and training of pharmacists in the area of pharmacovigilance can help address some of these difficulties [30], [31], [32]. For the purpose of raising the reporting rate and ensuring that potential drug-related issues are discovered and managed effectively, it is vital to implement reporting systems that are user-friendly and to provide ongoing education on the significance of adverse drug reaction reporting. There are a number of different techniques that may be employed in order to improve the pharmacovigilance practices that are carried out in community pharmacy. Enhancing the utilisation of technology, such as electronic health records and automated reporting systems, has the potential to simplify the process of reporting adverse drug reactions (ADRs) and enable more effective monitoring of these events. Pharmacists should also be encouraged to engage in training programmes and continuing professional development programmes that are centred on pharmacovigilance. Pharmacists can improve their ability to detect and effectively treat adverse drug reactions (ADRs) by participating in these programmes, which can help them stay current with the most recent breakthroughs in drug safety. When it comes to optimising pharmacovigilance processes, collaboration with other healthcare providers, such as physicians and nurses, is also quite important. The sharing of information, coordination of treatment, and more effective management of potential drug-related concerns are all possible outcomes that can be achieved when healthcare professionals collaborate. It is possible for interdisciplinary teamwork to result in a more complete management of adverse drug reactions (ADRs) and to contribute to improved patient care overall [33].

5. CONCLUSION

Pharmacovigilance in community pharmacies is vital for ensuring patient safety and optimizing medication use. Effective pharmacovigilance practices, including systematic ADR reporting, patient education, and collaboration with healthcare providers, are essential for identifying and managing adverse drug reactions, reducing adverse drug events, and enhancing overall healthcare quality. Despite the clear benefits, challenges such as underreporting and resource limitations must be addressed to improve the effectiveness of pharmacovigilance practices. Implementing strategies to overcome these challenges, including the use of technology, continuous professional development, and interdisciplinary collaboration, can enhance pharmacovigilance in community pharmacies. As the healthcare landscape evolves, the role of pharmacists in pharmacovigilance will remain crucial in safeguarding patient health and ensuring the safe and effective use of medications. Continued research and innovation in pharmacovigilance practices are necessary to advance pharmacy practice and enhance the role of pharmacists in patient care. By embracing their expanded roles and leveraging their expertise, pharmacists can significantly contribute to public health, reduce medication-related problems, and improve patient outcomes and quality of life.

Acknowledgments

The authors have no specific acknowledgments to make for this research.

Funding Information

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Author Contributions Statement

Name of Author	C	M	So	Va	Fo	I	R	D	O	E	Vi	Su	P	Fu
Fahad Nabi	✓	✓	✓			✓	✓	✓		✓	✓		✓	
Abrar Bashir Malik		✓	✓	✓			✓	✓		✓		✓		✓
Mohd Altaf Dar	✓	✓	✓	✓		✓	✓	✓		✓			✓	✓

C : **C**onceptualization
M : **M**ethodology
So : **So**ftware
Va : **Va**lidation
Fo : **Fo**rmal analysis
I : **I**nvestigation
R : **R**esources
D : **D**ata Curation
O : Writing - **O**riginal Draft
E : Writing - Review & **E**diting
Vi : **Vi**sualization
Su : **Su**pervision
P : **P**roject administration
Fu : **Fu**nding acquisition

Conflict of Interest Statement

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Informed Consent

All participants were informed about the purpose of the study, and their voluntary consent was obtained prior to data collection.

Ethical Approval

The study was conducted in compliance with the ethical principles outlined in the Declaration of Helsinki and approved by the relevant institutional authorities.

Data Availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

REFERENCES

[1] M. Zehravi and M. Maqbool, 'Polycystic ovary syndrome and infertility: an update', International journal of adolescent medicine and health, vol. 34, pp. 1-9, July 2021. doi.org/10.1515/ijamh-2021-0073

[2] R. J. Lihite et al., 'A study on adverse drug reactions in a tertiary care hospital of Northeast India. Alexandria journal of medicine', vol. 53, pp. 151-156, July 2017. doi.org/10.1016/j.ajme.2016.05.007

[3] M. Zehravi and M. Maqbool, 'Correlation between obesity, gestational diabetes mellitus, and pregnancy outcomes: an overview', International Journal of Adolescent Medicine and Health, vol. 33, no. 6, pp. 339-345, June 2021. doi.org/10.1515/ijamh-2021-0058

[4] M. Maqbool, F. Bekele, and G. Fekadu, 'Treatment strategies against triple-negative breast cancer: an updated review', Breast Cancer: Targets and Therapy, pp. 15-24, Jan. 2022. doi.org/10.2147/BCTT.S348060

[5] S. Rasool and M. Maqbool, 'An overview about Hedychium spicatum: a review', Journal of Drug Delivery and Therapeutics, vol. 9, pp. 476-480, Feb. 2019. doi.org/10.22270/jddt.v9i1-s.2429

[6] M. Zehravi and M. Maqbool, 'Depression and anxiety in women with polycystic ovarian syndrome: a literature survey', International Journal of Adolescent Medicine and Health, vol. 33, no. 6, pp. 367-373, Aug. 2021. doi.org/10.1515/ijamh-2021-0092

[7] M. Maqbool, I. Gani, and M. A. Dar, 'Anti-diabetic effects of some medicinal plants in experimental animals: a review', Asian Journal of Pharmaceutical Research and Development, vol. 7, no. 1, pp. 66-69, Feb. 2019. doi.org/10.22270/ajprd.v7i1.469

[8] M. Zehravi and M. Maqbool, 'Polycystic ovary syndrome and reproductive health of women: a curious association', International journal of adolescent medicine and health, vol. 33, pp. 333-337, Apr. 2021. doi.org/10.1515/ijamh-2021-0031

[9] M. Mohd, M. Maqbool, M. A. Dar, and I. Mushtaq, 'Polycystic ovary syndrome, a modern epidemic: an overview', Journal of Drug Delivery and Therapeutics, vol. 9, no. 3, pp. 641-644, May 2019. doi.org/10.22270/jddt.v9i3.2661

[10] M. Maqbool et al., 'An up to date on clinical prospects and management of osteoarthritis', Annals of Medicine and Surgery, vol. 72, Dec. 2021. doi.org/10.1016/j.amsu.2021.103077

[11] A. Majeed, R. Bashir, S. Farooq, and M. Maqbool, 'Preparation, characterization and applications of nanoemulsions: An insight', Journal of Drug Delivery and Therapeutics, vol. 9, no. 2, pp. 520-527, Mar. 2019. doi.org/10.22270/jddt.v9i2.2410

[12] M. Zehravi and M. Maqbool, 'Healthy lifestyle and dietary approaches to treating polycystic ovary syndrome: a review', Open Health, vol. 3, pp. 60-65, May 2022. doi.org/10.1515/openhe-2022-0008

[13] R. Maqbool, M. Maqbool, and M. Zehravi, 'Menstrual distress in females of reproductive age: a literature review', International journal of adolescent medicine and health, vol. 34, pp. 11-17, July 2021. doi.org/10.1515/ijamh-2021-0081

[14] I. Ara, M. Maqbool, G. Fekadu, T. A. Hajam, and M. A. Dar, 'Pharmaceutical significance of Nigella sativa L., a wonder herb', Journal of Applied Pharmaceutical Sciences and Research, vol. 3, no. 4, pp. 4-13, 2020. doi.org/10.31069/japsr.v3i4.2

[15] M. Maqbool, N. Nasir, and S. Mustafa, 'Polycystic in ovarian syndrome and its various treatment strategies', INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 5, no. 9, pp. 8470-8478, Sept. 2018.

[16] M. Maqbool, M. Zehravi, and R. Maqbool, 'Study of adverse drug reactions in pulmonary medicine department of a Tertiary care hospital', India. CELLMED, vol. 11, no. 2, pp. 8-9, 2021.

[17] I. Ara, M. Maqbool, B. Bukhari, and A. N. Hajam, 'Present status, standardization and safety issues with herbal drugs', International Journal of Research in Pharmaceutical Sciences and Technology, vol. 1, no. 3, pp. 95-101, May 2020. doi.org/10.33974/ijrpst.v1i3.169

[18] I. Ara, M. Maqbool, and I. Gani, 'Reproductive Health of Women: implications and attributes', International Journal of Current Research in Physiology and Pharmacology, pp. 8-18, Nov. 2022.

[19] M. Zehravi, R. Maqbool, and M. Maqbool, 'To Identify Patterns of Drug Usage among Patients Who Seek Care in Psychiatry Outpatient Department of a Tertiary Care Hospital in Srinagar, Jammu and Kashmir, India', Journal of Pharmaceutical Research International, vol. 33, no. 31A, pp. 135-140, June 2021. doi.org/10.9734/jpri/2021/v33i31A31673

[20] M. Maqbool, S. Javed, and A. A. Bajwa, 'Assessment OF pain management IN postoperative cases using different scales and questionnaires', INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 6, no. 1, pp. 983-987, Jan. 2019.

[21] I. Ara, M. Maqbool, and M. Zehravi, 'Psychic consequences of infertility on couples: A short commentary. Open Health', vol. 3, pp. 114-119, Jan. 2022. doi.org/10.1515/openhe-2022-0022

[22] R. Bashir, M. Maqbool, and A. I. Zehravi, 'An Insight into Novel Drug Delivery System: In Situ Gels', In Situ Gels. CELLMED, vol. 11, no. 1, pp. 6-7, 2021.

[23] M. Zehravi and M. Maqbool, 'Teenage menstrual dysfunction: an overview', International Journal of Adolescent Medicine and Health, vol. 35, no. 1, pp. 15-19, Sept. 2022. doi.org/10.1515/ijamh-2022-0018

[24] I. Ara, M. Zehravi, M. Maqbool, and I. Gani, 'A review of recent developments and future challenges in the implementation of universal health coverage policy framework in some countries', Journal of Pharmaceutical Research & Reports, no. 3, 2022.

[25] M. Maqbool, W. Shabbir, and S. Aamir, 'Adverse events of blood transfusion and blood safety in clinical practice', Indo American Journal of Pharmaceutical Sciences, vol. 5, no. 8, pp. 8254-8259, Aug. 2018.
[26] M. Maqbool, A. Naeem, and S. Aamer, 'Diabetes mellitus and its various management strategies in practice', Indo American Journal of Pharmaceutical Sciences, vol. 5, no. 8, Aug. 2018.
[27] M. Maqbool, S. Tariq, and S. Amjad, 'Prescribing practices in pediatrics and drug utilization studies promoting pediatric health', Indo American Journal of Pharmaceutical Sciences, vol. 5, no. 8, pp. 8070-8076, Aug. 2018.
[28] M. Maqbool, U. Ikram, and A. Anwar, 'Adverse drug reaction monitoring and occurrence in drugs used in pulmonary disorders', Indo American Journal of Pharmaceutical Sciences, vol. 5, no. 8, pp. 8060-8065, Aug. 2018.
[29] R. Maqbool, M. Maqbool, and M. Zehravi, 'Acute neurological conditions during pregnancy and their management: a review', International Journal of Adolescent Medicine and Health, vol. 33, no. 6, pp. 357-366, Aug. 2021. doi.org/10.1515/ijamh-2021-0084
[30] M. Zehravi and M. Maqbool, 'An overview about safety surveillance of adverse drug reactions and pharmacovigilance in India', The Indian Journal of Nutrition and Dietetics, pp. 408-418, July 2021. doi.org/10.21048/IJND.2021.58.3.27285
[31] M. Maqbool and M. Zehravi, 'Neuroprotective role of polyphenols in treatment of neurological disorders: A review. Interventional Pain Medicine and Neuromodulation', vol. 1, Dec. 2021. doi.org/10.5812/ipmn.117170
[32] M. Maqbool and A. I. Gani, 'The Story of Polycystic Ovarian Syndrome: A Challenging Disorder with Numerous Consequences for Females of Reproductive Age', International Journal of Current Research in Physiology and Pharmacology, pp. 19-31, Nov. 2022.
[33] M. Maqbool and I. Gani, 'Utilization of statins in reducing comorbidities of diabetes mellitus: A systematic review', Journal of Pharmacy Practice and Community Medicine, vol. 4, no. 4, 2018. doi.org/10.5530/jppcm.2018.4.46

How to Cite: Fahad Nabi, Abrar Bashir Malik, Mohd Altaf Dar. (2023). Safeguarding health: The impact of pharmacovigilance practices in community pharmacies. Journal of Community Pharmacy Practice (JCPP), 3(1), 62-70. https://doi.org/10.55529/jcpp.33.24.32

BIOGRAPHIES OF AUTHORS

	**Fahad Nabi**, is affiliated with the Department of Pharmacology, CT Institute of Pharmaceutical Sciences, PTU, Jalandhar, Punjab, India. His academic and research interests focus on pharmacology, drug discovery, therapeutic evaluation, and pharmaceutical sciences. He is actively involved in scientific research exploring pharmacological mechanisms and the therapeutic potential of bioactive compounds and drugs. His work aims to contribute to advancements in pharmacological research through systematic experimentation, scientific analysis, and collaborative research.
	**Abrar Bashir Malik**, is affiliated with the Department of Pharmacology, CT Institute of Pharmaceutical Sciences, PTU, Jalandhar, Punjab, India. His research interests encompass pharmacology, drug development, therapeutic investigations, and pharmaceutical sciences. He is involved in academic and scientific research focused on understanding pharmacological effects and evaluating potential therapeutic agents. His contributions support the development of knowledge in pharmacology through systematic research, scientific analysis, and collaboration with researchers in pharmaceutical sciences.

	**Mohd Altaf Dar, ** is affiliated with the Department of Pharmacology, CT Institute of Pharmaceutical Sciences, PTU, Jalandhar, Punjab, India. His academic and research interests include pharmacology, drug discovery, therapeutic evaluation, and pharmaceutical research. He is involved in scientific investigations aimed at understanding drug actions, pharmacological mechanisms, and potential therapeutic applications. His research contributes to the advancement of pharmaceutical sciences through experimental studies, scholarly collaboration, and the application of modern research methodologies. Email: daraltaf490@gmail.com